> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Merck, Moderna Developing Personalized Cancer Vaccine
- URL: https://www.fdaweb.com/merck-moderna-developing-personalized-cancer-vaccine/
- Published: 2022-10-12T12:00:00.000Z
- Updated: 2026-09-14T18:02:47.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5152956

Merck has exercised its option to join with Moderna to develop and commercialize a personalized cancer vaccine currently being evaluated in combination with Merck’s Keytruda (pembrolizumab), an anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Moderna Phase 2 trial. A Merck [statement](https://www.merck.com/news/merck-and-moderna-announce-exercise-of-option-by-merck-for-joint-development-and-commercialization-of-investigational-personalized-cancer-vaccine/?ref=fdaweb.com) says personalized cancer vaccines are designed to prime the immune system so that a patient can generate a tailored antitumor response to the tumor mutation signature to treat their cancer. Moderna’s mRNA-4157/V940 is designed to stimulate an immune response by generating T-cell responses based on the mutational signature of a patient’s tumor, the statement says.